AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04504045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: As part of a 6-drug cocktail caffeine 100 mg tablet will be administered as a single dose before the initiation of metformin treatment and 3 weeks and 12 weeks after. The drug will be used as a probe to assess CYP1A2 activity.
Study NCT04504045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: As part of a 6-drug cocktail efavirenz 50 mg coated tablet will be administered as a single dose before the initiation of metformin treatment and 3 weeks and 12 weeks after. The drug will be used as a probe to assess CYP2B6 activity.
Study NCT04504045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: As part of a 6-drug cocktail losartan 12.5 mg coated tablet will be administered as a single dose before the initiation of metformin treatment and 3 weeks and 12 weeks after. The drug will be used as a probe to assess CYP2C9 activity.
Study NCT04504045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazol
Description: As part of a 6-drug cocktail Omeprazol 10 mg enteric-coated tablet will be administered as a single dose before the initiation of metformin treatment and 3 weeks and 12 weeks after. The drug will be used as a probe to assess CYP2C19 activity.
Study NCT04504045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol
Description: As part of a 6-drug cocktail metoprolol 12.5 mg release tablet will be administered as a single dose before the initiation of metformin treatment and 3 weeks and 12 weeks after. The drug will be used as a probe to assess CYP2D6 activity.
Study NCT04504045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: As part of a 6-drug cocktail midazolam 2 mg oral solution will be administered as a single dose before the initiation of metformin treatment and 3 weeks and 12 weeks after. The drug will be used as a probe to assess CYP3A4 activity.
Study NCT03085563 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrous Oxide
Description: Nitrous oxide will be delivered in one of two ways, using the titration method or rapid infusion method. Which ever method is used will be recorded. When using the titration method, starting at 20%, nitrous oxide will be added in 10% increments every 60 seconds until the ideal level of sedation has been met (not to exceed 70% nitrous oxide). Using the rapid infusion method, after the proper flow rate has been achieved with oxygen, the flowmeter will be increased to obtain 50% concentration of nitrous oxide. After 2-3 minutes if the patient does not have adequate sedation, nitrous oxide concentration will be increased to 70%.
Study NCT03085563 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Intranasal midazolam with mucosal atomizer device administration will follow the Children's Hospital Colorado (CHCO) established policy 'Intranasal Administration (atomization) of Medications'. As per standard of care, each patient will receive a standardized dose of 0.4mg/kg (maximum dose of 10mg) of intranasal midazolam with the mucosal atomizer device for all procedures.
Study NCT01226745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4641
Description: Subjects will be administered with ONO-4641 at a dose of 0.15 milligram (mg) in the core study will be administered with ONO-4641 0.15 mg in this extension study for a duration of 225 weeks.
Study NCT01226745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4641
Description: Subjects will be administered with ONO-4641 at a dose of 0.10 mg in the core study will be administered with ONO-4641 0.10 mg in this extension study for a duration of 225 weeks.
Study NCT01226745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4641
Description: Subjects will be administered with ONO-4641 at a dose of 0.05 mg in the core study will be administered with ONO-4641 0.05 mg in this extension study for a duration of 225 weeks.
Study NCT01226745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4641
Description: Subjects will receive placebo in the core study will be administered with ONO-4641 0.15 mg in this extension study for a duration of 225 weeks.
Study NCT01226745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4641
Description: Subjects will receive placebo in the core study will be administered with ONO-4641 0.10 mg in this extension study for a duration of 225 weeks.
Study NCT01226745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4641
Description: Subjects will receive placebo in the core study will be administered with ONO-4641 0.05 mg in this extension study for a duration of 225 weeks.
Study NCT04191772 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Periodized, home-based running program
Description: All participants will perform a home-based supervised exercise training program. Participants will receive weekly training instructions using a smartphone-based heart rate monitor application (Polar® app). Training sessions will involve running and the design of the training program will be based on linear periodization, where aerobic capacity is built firstly through a period of high-volume/low-intensity training before the proportion of high-intensity training is increased. The total duration of the exercise program will be 12 months with three weekly training sessions. Training progression will be dependent on initial VO2max values and running experience. VO2max classification is based on reference values described in V.H. Heyward, Advanced Fitness Assessment and Exercise Prescription, Fifth Edition, 2006, Champaign, IL: Human Kinetics.
Study NCT03414307 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intracerebral catheter placement
Description: Image guided stereotactic placement of intra-hemorrhage catheters to evacuate intra-cerebral hemorrhage
Study NCT03414307 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot-assisted intracerebral catheter
Description: ROSA is a robotic device with trajectory planning software that can be used to aid in planning multiple trajectories to large, irregular clots, and aids in navigating into and out of the cerebral hematoma with minimum human error.
Study NCT00704990 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc, Magnesium, Vitamin B6, Vitamin C (Compound Natural Health Product for ADHD)
Description: Weight based dosing of a chewable natural health product containing 15-35 mg zinc citrate, 150-350 mg magnesium lactate, 30-70 mg pyridoxine hydrochloride and 150-350 mg calcium ascorbate. Participants will take weight based dose two times during the day with meals for a 10 week period
Study NCT00779844 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bariatric coelioscopic surgical procedure
Description: total intra-venous anesthesia (propofol and remifentanil) being delivered using a close-loop system with the Bispectral Index as the single input for the controller
Study NCT00779844 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: supra-umbilical coelioscopic surgical procedure
Description: total intra-venous anesthesia (propofol and remifentanil) being delivered using a closed-loop system with the Bispectral Index as the single input for the controller
Study NCT00267020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzastaurin
Description: 1200 milligrams (mg) loading dose then 500 mg, orally, daily, six 28-day cycles
Study NCT00267020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 1000 milligrams/square meter (mg/m\^2), intravenously on Days 1, 8 and 15 per cycle, six 28-day cycles
Study NCT00267020 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine
Description: 1000 milligrams/square meter (mg/m\^2), intravenously on Days 1, 8 and 15 per cycle, six 28-day cycles
Study NCT04622488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Potassium
Description: - In the form of Insitu gel system can be applied as solution or suspension that undergoes gelation after administration. Applied once inside the root canal after chemo-mechanical preparation.
Study NCT04622488 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac Potassium
Description: - In the form of Insitu gel system can be applied as solution or suspension that undergoes gelation after administration. Applied once inside the root canal after chemo-mechanical preparation.
Study NCT03755245 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: [68Ga]Ga-DOTA-Siglec-9
Description: Vascular Adhesion Protein 1 (VAP-1) targeted radiopharmaceutical
Study NCT00293475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IA
Study NCT00293475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannitol
Description: Given IA
Study NCT00293475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IA
Study NCT00293475 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT00293475 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT00293475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Thiosulfate
Description: Given IV
Study NCT03673475 — intervention group
Intervention type: PROCEDURE
Intervention: Assessment of fluid responsiveness
Description: assessment of intravascular volume status using pleth variebility index and internal jugular vein distensibility in major abdominal surgery
Study NCT03176303 — intervention group
Intervention type: DEVICE
Intervention: SpinalStim
Description: PEMF osteogenesis stimulator
Study NCT00832923 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PEPAC
Description: The proposed enhancement of the IMPACT DC intervention will consist of three key components: (1) an enhanced IMPACT DC Asthma Clinic visit; (2) short-term case management to increase the rate of primary care follow-up visits in the first month after the IMPACT DC Asthma Clinic visit; and (3) training in an asthma care toolkit to improve communication around asthma care with the child's primary care provider.
Study NCT04307186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadoquatrane (BAY1747846)
Description: Solution for IV injection, single dose
Study NCT04307186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobutrol (Gadovist/Gadavist)
Description: Solution for IV injection, single dose
Study NCT01456000 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EAS-AC (HeartLight)
Description: Pulmonary vien isolation
Study NCT01456000 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control Arm Ablation
Description: Treatment with standard ablation.
Study NCT02106468 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone tablet 5mg
Description: This group included 15 patients who received prednisone (Delta-cortene Fort®, Lepetit, Carmano, Melano, Italy) at 40mg /day (8 tablets/day in divided dose , 4 tablet at morning and 4 at evening) for 6 weeks then 20mg/day for 2 week then to 10 mg/day for 2 week, and finally to 5 mg /day for the last 2 weeks.
Study NCT02106468 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 soft capsules 1000 mg
Description: This group included 15 patients who received Omega-3 soft gelatin capsules 1000 mg (Super Omega; Technopharma, Cairo, Egypt). The patients received instruction to take one capsule three times daily for 3 months.
Study NCT03146169 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training group
Description: The training workshop includes four two-hour sessions:~Session one - a knowledge, self-efficacy, and motivation enhancement session at baseline; Session two - an interpersonal communication and leadership skills session at one week; Session three - a motivation enhancement session at one month Session four - an experience sharing session at three months
Study NCT02461121 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: HLA mismatched stem cell
Description: HLA mismatched donor G-CSF mobilized peripheral stem cell infused 24 hours (day 0) after the completion of chemotherapy
Study NCT02461121 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: HLA matched stem cell
Description: HLA matched donor G-CSF mobilized peripheral stem cell infused after the conditioning reginmen
Study NCT03496935 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tunneled versus non-tunneled dialysis catheter insertion
Description: The study participants will be randomized either to tunneled or non-tunneled dialysis catheter insertion to commence renal replacement therapy for an acute kidney injury requiring either continuous or intermittent dialysis in the ICU.
Study NCT02484235 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIIT
Description: Group training with HIIT 3 times per week during 10 sessions
Study NCT02484235 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength
Description: Group training with strength exercises 3 times per week during 10 sessions
Study NCT02038959 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Visits
Description: Virtual visits will be completed using HIPAA-compliant video conferencing software from SBR Health and Vidyo, designed specifically for use in the healthcare industry. The software is available for Windows and Mac OS, as well as iOS devices (iPad and iPhone).
Study NCT00915473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivicaine
Description: 2.5 mL 0.5% bupivicaine
Study NCT00915473 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: 2.75 mL normal saline
Study NCT00915473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: 0.5 mL 20 mg methylprednisolone
Study NCT00915473 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: lidocaine
Description: 0.25 mL 1% lidocaine
Study NCT02344459 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: mechanical pre-induction cervical ripening
Description: The balloon catheters have been used to provide mechanical dilation to the cervix as a method of pre-induction cervical ripening.
Study NCT02344459 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mechanical pre-induction cervical ripening
Description: The balloon catheters have been used to provide mechanical dilation to the cervix as a method of pre-induction cervical ripening.
Study NCT02253407 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MMR vaccine
Study NCT02253407 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MMR vaccine
Study NCT03944018 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention with rehabilitation coordinator
Description: Intervention with rehabilitation coordinator in orthopedic care
Study NCT02845973 — intervention group
Intervention type: BIOLOGICAL
Intervention: gut microbiota
Study NCT01379079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid
Description: aspirin intake at bedtime
Study NCT01379079 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic acid lysinate
Description: aspirin intake on awakening
Study NCT02331069 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextrose 5% (D5W)
Description: 0,1,2, and 3 week injection sessions consisting of injection of 2 ml of D5W into the D-T groove at the point of maximal pain at 1-2 cm depth, followed by subcutaneous injection of D5W at 4 cm intervals along the course of the PACN if tenderness is present.
Study NCT02331069 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy
Description: Three times weekly X 3 week sessions to include myofascial release, exercise, and one modality.
Study NCT02228746 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alpha-galacto-oligosaccharides
Description: 6g of alpha-galacto-oligosaccharides in a 100 mL flavored drink
Study NCT02866123 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ultrasonography
Study NCT00471224 — intervention group
Intervention type: OTHER
Intervention: Observational Trial
Description: No intervention is being used in this study.
Study NCT01277601 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TDF
Description: TDF 300 mg tablets administered orally once daily
Study NCT01277601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDF
Description: TDF 300 mg tablets administered orally once daily
Study NCT01277601 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peg-IFN
Description: Peg-IFN 180 µg administered via subcutaneous injection once weekly
Study NCT02866123 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: pulmonary radiography
Study NCT02461121 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporine A
Description: The GVHD prophylaxis included cyclosporine A and mycophenolate mofetil
Study NCT02461121 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil
Description: The GVHD prophylaxis included cyclosporine A and mycophenolate mofetil
Study NCT02461121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ara-C
Description: 2.0 to 3.0g/m2 per 12 hours intravenously for 6 dose
Study NCT02461121 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ara-C
Description: 2.0 to 3.0g/m2 per 12 hours intravenously for 6 dose
Study NCT01858558 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aMIL
Description: On day 0, patients will receive auto transplant followed by Tadalafil and aMIL. At day 60, patients will receive Lenalidomide.
Study NCT01858558 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: No aMIL
Description: On day 0, patients will receive auto transplant followed by Tadalafil. At day 60, patients will receive Lenalidomide.
Study NCT01858558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: No aMIL
Description: On day 0, patients will receive auto transplant followed by Tadalafil. At day 60, patients will receive Lenalidomide.
Study NCT03190018 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: lCarry Life System Peritoneal Dialysis (CLS PD)
Description: The assigned intervention is with the CLS PD device in patients currently receiving peritoneal dialysis for the duration of one study session. A temporary Pigtail catheter is inserted on the same morning as the study session and removed after the session on the same day.
Study NCT02818179 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: THERMOGRAPHY IMAGING
Study NCT01297569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Study NCT05591456 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: adjuvant radiotherapy
Description: Treatment schedule and delivery The patients who met the inclusion criteria were randomly divided into two groups, each group of 50 patients. The first group (arm A) will receive a dose of 27 Gy to the chest wall using 3D conformal radiotherapy (5.4 Gy per fraction) over one week, whilst, the second group (arm B) will receive a dose of 40 Gy to the chest wall (2.67 Gy per fraction) over three weeks.
Study NCT05145088 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: submaximal exercise testing according to ACSM guidelines
Description: For Moderate-intensity exercises includes either 30 min a day for five days a week or a total of two hours and 30 min per week using 50% to 70% of maximum heart rate
Study NCT03751527 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ZENFLEX peripheral stent system
Description: The ZENFLEX Peripheral Stent System is designed to deliver a self-expanding stent to the iliac artery, superficial femoral arteries and / or proximal popliteal arteries to improve luminal diameter. The self-expanding stent is composed of nickel titanium alloy (nitinol); contains a total of 12 tantalum / gold radiopaque markers and imparts an outward radial force on the luminal surface of the vessel to establish patency.
Study NCT00406107 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegaptanib sodium (Macugen)
Description: Subjects were randomized 3:1 to intravitreous injections of pegaptanib 0.3mg or 1mg at baseline and at weeks 6 and 12 with subsequent injections at 6-week intervals at investigator discretion until week 48.
Study NCT02846740 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alpha-Stim®.
Description: cranial electrical stimulation
Study NCT02846740 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Alpha-Stim®.
Description: cranial electrical stimulation
Study NCT02846740 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Montgomery-Åsberg Depression Rating Scale, Hamilton Anxiety Rating Scale, The Pittsburgh Sleep Quality Index and agitated behavior Scale
Description: A summed global score from rating scales measuring the Modifiable suicide risk factors (MSRF's).
Study NCT02846740 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Montgomery-Åsberg Depression Rating Scale, Hamilton Anxiety Rating Scale, The Pittsburgh Sleep Quality Index and agitated behavior Scale
Description: A summed global score from rating scales measuring the Modifiable suicide risk factors (MSRF's).
Study NCT02507258 — intervention group
Intervention type: DEVICE
Intervention: PROFEMUR® Am Femoral Stem w/ PROCOTYL® O Shell
Description: PROFEMUR® Am cementless stems with PROCOTYL® O HA Coated Acetabular Component
Study NCT03865992 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: Given capsules for oral administration